New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:41 EDTARGSArgos says treatment with AGS-003, sunitinib improved expected mRCC survival
Argos Therapeutics announced updated results from a completed phase 2 study highlighting the long-term survival observed in patients treated with sunitinib combined with AGS-003, the company's investigational fully personalized immunotherapy for cancer. Results were presented in a poster presentation at the American Society of Clinical Oncology Annual Meeting on Friday, May 30. According to the results of the study titled "Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib," presented by lead author Asim Amin, MD, PhD, treatment with AGS-003 in combination with sunitinib in an unfavorable risk mRCC patient population, resulted in median progression free survival of 11.2 months and median overall survival of 30.2 months. Based upon recently published findings from the International mRCC Database Consortium, similar risk mRCC patients with a time from diagnosis to treatment of less than one year risk factor have an expected median PFS of 5.7 months and median OS of 14.7 months. In addition, 33% of patients survived for greater than 4.5 years and 23% for more than five years, with two patients remaining in long-term remission for longer than five years following continued dosing with AGS-003. Adverse events associated with the use of AGS-003 were minor with no grade 3 or 4 AEs and no evidence of autoimmunity. "These results showing the potential for AGS-003 to double the expected PFS, OS and extend long-term survival in unfavorable risk mRCC, provide strong support for the ongoing, pivotal ADAPT phase 3 trial. Our goal at Argos is to bring this promising, fully personalized immunotherapy to mRCC patients as quickly as possible to address persistent unmet needs in current standard of care," said Jeff Abbey, CEO and president of Argos Therapeutics.
News For ARGS From The Last 14 Days
Check below for free stories on ARGS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 8, 2014
08:44 EDTARGSArgos Therapeutics issued patent for Arcelis technology platform
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use